Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapyJames R. Berenson, Robert Vescio, James Hilger et al.|Leukemia|2014Cited by 76
Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R. Berenson, Debra Mayo, Ori Yellin et al.|British Journal of Haematology|2012Cited by 53
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapyJonathan W. Friedberg, Christopher A. Yasenchak, Dipti Patel‐Donnelly et al.|Blood|2023Cited by 42
Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma PatientsChristopher A. Yasenchak, Jonathan W. Friedberg, Rodolfo Bordoni et al.|Blood|2020Cited by 16
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 StudyJames R. Berenson, Debra Mayo, Ori Yellin et al.|Blood|2011Cited by 6